IndraLab
Statements
USP35 activates Breast Neoplasms. 2 / 2
|
2
reach
"Our results demonstrated that BRD4 inhibition with (+)-JQ-1 treatment significantly inhibited the ER+ breast tumors enhanced by USP35 overexpression, along with decrease of SLC7A11 protein level, and increase of 4-HNE protein levels (Fig. 7), supporting that BRD4 mediated USP35 inhibition of ferroptosis in ER+ breast tumors.Reported studies have shown SLC7A11 expression can be regulated at translational and post-translational levels ."